Success of Centralized Manufacturing of CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed/Refractory AML (TCT-ASTCT-CIBMTR 2024) - Dec 12, 2023 - Abstract #198; Pres time: Feb 22, 2024; 06:45 PM - 07:45 PM; Location: Exhibit Hall 4a (Street Level); In-Person; P1/2 | "Despite wide inter-patient heterogeneity of apheresis products, centralized manufacturing of CD33CART was feasible in children and young adults with r/r AML. Correlative analyses characterizing CD33CART products are ongoing."
CAR T-Cell Therapy • Clinical • Acute Myelogenous Leukemia • CD4 • CD8 • IL2
|
|
Brian Bowser, PhD1; Xiaoyi Yang2; John Roach2; Julie Blake2; Kate Donnelly3; Brenna Paskey3; Heidi VanBockel3; Bonnie Yates, MSN, CNP4; Chloe Hoang5; Sarah K Tasian, MD6; Katherine Tarlock7; Susanne H.C. Baumeister, MD8; Emily M. Hsieh, MD9; Michael R. Verneris, MD10; Hati K Kobusingye, MS11; Allison Weiss12; Larisa Broglie, MD, MS13; Steven M. Devine, MD14; Richard Aplenc, MD, PhD15; Sheryl Ruppel2; Anthony Welch, PhD16; Jason Yovandich16; Nirali N. Shah, MD, MHSc4; Rachelle Salomon, PhD16; George Mitra16
|